MAP2K3 and colorectal carcinoma: At molecular levels, we demonstrated that AT9283 treatments abrogated the MKK3 protein levels mainly through the targeting of the AURKA signalling, shedding lights on the relevance of MKK3/AURKA crosstalk in sustaining CRC malignancy.